Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
111 study: one cycle adjuvant BEP in high-risk stage I non-seminomatous testicular germ cell tumors
ISRCTN37875250Phase 3Completed
- Sponsor
- The Institute of Cancer Research
- Start
- Jun 2009
- Modality
- Small Molecules
01
Overview
Phase 3, open-label, single-arm trial of bleomycin, etoposide and cisplatin in Nonseminomatous Testicular Cancer (NSGCT) and Mixed germ cell cancer (MGCT), sponsored by The Institute of Cancer Research. Primary endpoint: Recurrence at 2 years. Started Jun 2009; status: completed.
02
Drugs
bleomycinetoposidecisplatin
03
Conditions
Nonseminomatous Testicular Cancer (NSGCT)Mixed germ cell cancer (MGCT)
Beyond the preview
Go deeper on ISRCTN37875250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN37875250.